flanders.bio is the cluster organisation empowering a life sciences driven network economy

flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.

News from flanders.bio and its members

Belgium showcases expertise on Immunotherapy at the world’s largest Biotechnology Conference – San Diego, June 19- 23, 2017

Yes, Belgium is a hotspot for innovative biopharma and biotechnology industry and we house all the right ingredients for a successful ecosystem: topnotch academic research centers, a large community of SMEs and last but not least: the top-10 biopharma companies all have key activities in Belgium: Novartis, Pfizer, Roche, Sanofi, Merck & C°, Johnson & Johnson, GSK, AstraZeneca, UCB and AbbVie.

People | 15 June 17 Read more

Estelle® Phase IIB results on well-being and body weight published in leading peer-reviewed journal

Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, announces that the European Journal of Contraception and Reproductive Health Care, one of the most prestigious peer-reviewed journals in the field, has published an article1 detailing the acceptability, user satisfaction, well-being and body weight control of Estelle® in the Phase IIb FIESTA study. Estelle® is Mithra’s combined oral contraceptive (COC) candidate, composed of 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP). Estelle® is currently being tested in two Phase III trials in Europe/Russia and in the US/Canada, the results of which should be available in Q3 2018 and Q1 2019, respectively.

Ablynx initiates a single and multiple dose phase I study of caplacizumab in healthy Japanese subjects

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that the first Japanese healthy volunteers have been dosed in the Phase I single centre, randomised, double-blind, placebo-controlled study of caplacizumab, its first-in-class anti-von Willebrand factor (vWF) Nanobody® being developed for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).

Research | 26 June 17 Read more

Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform

BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that the European Patent Office (EPO) has notified the Company of its intention to grant a key patent covering its first-in-class allogeneic cell therapy technology.

TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces that Dr. Marie Paule Richard, Chief Medical Officer of TiGenix, will be speaking at the 7th TERMIS-EU Industry Day taking place from June 26-30, 2017 at the Davos Conference Center, Switzerland.

Research | 23 June 17 Read more

flanders.bio events, trainings & international missions

Strategic Partners